Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rare Lymphoma Risk Haunts Remicade Expansion To Pediatric Ulcerative Colitis

Executive Summary

Determining how to handle the risk of rare, but deadly, hepatosplenic T-cell lymphoma with Centocor’s Remicade (infliximab) will be one of the tasks FDA faces as it decides whether to expand the biologics’ indication for ulcerative colitis to pediatric patients.

You may also be interested in...

Humira Will Get Advisory Committee Review For Ulcerative Colitis

FDA’s Gastrointestinal Drugs Advisory Committee is scheduled to review Abbott’s sNDA for the TNF blocker Humira Aug. 28.

FDA Boosts Surveillance Requirements For TNF Blockers In Effort To Track Lymphoma

Manufacturers must conduct in-depth follow-up of reported malignancies in children and young adult patients and submit them to FDA within 15 days of learning about the cases.

FDA Advisory Committee Waivers Reflect Recruitment Challenges

Recent waivers allowing the participation of outside experts at drug-related advisory committee meetings reflect FDA's difficulties in finding qualified individuals to provide advice on specialized topics.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts